Advertisement

Head and Neck Pathology

, 3:263 | Cite as

Her-2 Immunohistochemical Expression in Oral Squamous Cell Carcinomas is Associated with Polysomy of Chromosome 17, Not Her-2 Amplification

  • Dimitrios Papavasileiou
  • Konstantinos Tosios
  • Panos Christopoulos
  • Nikolaos Goutas
  • Dimitrios Vlachodimitropoulos
Original Paper

Abstract

Based on the prognostic role of Her-2 amplification and protein overexpression in breast cancer, various studies have been performed in oral squamous cell carcinomas (OSCC) with inconsistent results. As in invasive breast carcinomas Her-2 overexpression has been related to an increased number of chromosome 17 copies, a common chromosomal alteration in OSCC, we evaluated the association between polysomy 17 and Her-2 protein expression in a series of primary OSCC. Forty-one incisional biopsies of primary OSCC were included in the study. Protein expression was evaluated immunochistochemically with CB11 mouse monoclonal anti-human antibody. The reaction was arbitrarily characterized as absent, faint, moderate, and strong, and staining pattern as cytoplasmic and membranous. Positive cases were analyzed by chromogenic in situ hybridisation (CISH) to access Her-2 status. The association between polysomy 17 and Her-2 expression was checked by Fisher’s exact test. Four cases were negative and 37 cases were positive for Her-2. Staining was faint in 15 cases and moderate in 22 cases. CISH showed that all cases with faint staining were diploid, while from the cases with moderate staining 10 were diploid and 12 polysomic for chromosome 17. Thirteen cases showed purely cytoplasmic staining, while in 24 there were areas of both cytoplasmic and membranous staining. There was a statistically significant correlation between intensity of the reaction and polysomy 17 (P = 0.0036), in particular for cases with both cytoplasmic and membranous staining (P = 0.0128). In some OSCC Her-2 immunohistochemical expression may be associated with chromosome 17 polysomy and not Her-2 amplification.

Keywords

Her-2 Gene Genetic abnormalities Oral squamous cell carcinoma Immunohistochemistry Hybridization in situ 

References

  1. 1.
    Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312:513–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12(Suppl 1):S3–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Casalini P, Iorio MV, Galmozzi E, et al. Role of HER receptors family in development and differentiation. J Cell Physiol. 2004;200:343–50.CrossRefPubMedGoogle Scholar
  4. 4.
    O-Charoenrat P, Rhys-Evans PH, Modjtahedi H, et al. The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol. 2002;38:627–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Salido M, Tusquets I, Corominas JM, et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res. 2005;7:R267–73.CrossRefPubMedGoogle Scholar
  6. 6.
    Craven JM, Pavelic ZP, Stambrook PJ, et al. Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res. 1992;12:2273–6.PubMedGoogle Scholar
  7. 7.
    Beckhardt RN, Kiyokawa N, Xi L, et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1995;121:1265–70.PubMedGoogle Scholar
  8. 8.
    Xia W, Lau YK, Zhang HZ, et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res. 1997;3:3–9.PubMedGoogle Scholar
  9. 9.
    Ibrahim SO, Vasstrand EN, Liavaag PG, et al. Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res. 1997;17:4539–46.PubMedGoogle Scholar
  10. 10.
    Xia W, Lau YK, Zhang HZ, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res. 1999;5:4164–74.PubMedGoogle Scholar
  11. 11.
    Giatromanolaki A, Koukourakis MI, Sivridis E, et al. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival. Anticancer Res. 2000;20:997–1004.PubMedGoogle Scholar
  12. 12.
    Hoffmann TK, Ballo H, Braunstein S, et al. Serum level and tissue expression of c-erbB-1 and c-erbB-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck. Oral Oncol. 2001;37:50–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Khademi B, Shirazi FM, Vasei M, et al. The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Lett. 2002;184:223–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Kuropkat C, Venkatesan TK, Caldarelli DD, et al. Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx. Auris Nasus Larynx. 2002;29:165–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Khan AJ, King BL, Smith BD, et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2002;8:540–8.PubMedGoogle Scholar
  16. 16.
    Nagler RM, Kerner H, Laufer D, et al. Squamous cell carcinoma of the tongue: the prevalence and prognostic roles of p53, Bcl-2, c-erbB-2 and apoptotic rate as related to clinical and pathological characteristics in a retrospective study. Cancer Lett. 2002;186:137–50.CrossRefPubMedGoogle Scholar
  17. 17.
    Scheer M, Prange W, Petmecky K, et al. Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence in situ hybridization (FISH) and immunohistochemistry. Mund Kiefer Gesichtschir. 2003;7:138–45.PubMedGoogle Scholar
  18. 18.
    Parise Junior O, Carvalho LV, Miguel RE, et al. Prognostic impact of p53, c-erbB-2 and epidermal growth factor receptor on head and neck carcinoma. Sao Paulo Med J. 2004;122:264–8.PubMedGoogle Scholar
  19. 19.
    Schartinger VH, Kacani L, Andrle J, et al. Pharmacodiagnostic value of the HER family in head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2004;66:21–6.PubMedGoogle Scholar
  20. 20.
    Ulanovski D, Stern Y, Roizman P, et al. Expression of EGFR and Cerb-B2 as prognostic factors in cancer of the tongue. Oral Oncol. 2004;40:532–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Bei R, Budillon A, Masuelli L, et al. Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol. 2004;204:317–25.CrossRefPubMedGoogle Scholar
  22. 22.
    Cavalot A, Martone T, Roggero N, et al. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck. 2007;29:655–64.CrossRefPubMedGoogle Scholar
  23. 23.
    Rautava J, Jee KJ, Miettinen PJ, et al. ERBB receptors in developing, dysplastic and malignant oral epithelia. Oral Oncol. 2008;44:227–35.CrossRefPubMedGoogle Scholar
  24. 24.
    Angiero F, Sordo RD, Dessy E, et al. Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters? J Oral Pathol Med. 2008;37:145–50.PubMedGoogle Scholar
  25. 25.
    Nunes CB, Rocha RM, Reis-Filho JS, et al. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J Clin Pathol. 2008;61:934–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Varshney D, Zhou YY, Geller SA, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 2004;121:70–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Ekberg T, Nestor M, Engstrom M, et al. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol. 2005;26:1177–85.PubMedGoogle Scholar
  28. 28.
    Albuquerque RL Jr, Miguel MC, Costa AL, et al. Correlation of c-erbB-2 and S-100 expression with the malignancy grading and anatomical site in oral squamous cell carcinoma. Int J Exp Pathol. 2003;84:259–65.CrossRefPubMedGoogle Scholar
  29. 29.
    Do NY, Lim SC, Im TS. Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck. Oncol Rep. 2004;12:229–37.PubMedGoogle Scholar
  30. 30.
    Kilpi A, Rich AM, Konttinen YT, et al. The expression of c-erbB-2 protein in the keratinocytes of oral mucosal lichen planus. Br J Dermatol. 1995;133:847–52.CrossRefPubMedGoogle Scholar
  31. 31.
    Kilpi A, Rich AM, Konttinen YT, et al. Expression of c-erbB-2 protein in keratinocytes of oral mucosal lichen planus and subsequent squamous cell carcinoma. Eur J Oral Sci. 1996;104:278–84.CrossRefPubMedGoogle Scholar
  32. 32.
    Wilkman TS, Hietanen JH, Malmstrom MJ, et al. Immunohistochemical analysis of the oncoprotein c-erbB-2 expression in oral benign and malignant lesions. Int J Oral Maxillofac Surg. 1998;27:209–12.CrossRefPubMedGoogle Scholar
  33. 33.
    Hou L, Shi D, Tu SM, et al. Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett. 1992;65:215–20.CrossRefPubMedGoogle Scholar
  34. 34.
    Freier K, Bosch FX, Flechtenmacher C, et al. Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: a tissue microarray analysis. Anticancer Res. 2003;23:3971–7.PubMedGoogle Scholar
  35. 35.
    Rodrigo JP, Ramos S, Lazo PS, et al. Amplification of ERBB oncogenes in squamous cell carcinomas of the head and neck. Eur J Cancer. 1996;32A:2004–10.CrossRefPubMedGoogle Scholar
  36. 36.
    Leonard JH, Kearsley JH, Chenevix-Trench G, et al. Analysis of gene amplification in head-and-neck squamous cell carcinoma. Int J Cancer. 1991;48:511–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol. 2006;19:634–40.CrossRefPubMedGoogle Scholar
  38. 38.
    O-Charoenrat P, Rhys-Evans P, Eccles S. Characterization of ten newly-derived human head and neck squamous carcinoma cell lines with special reference to c-erbB proto-oncogene expression. Anticancer Res. 2001;21:1953–63.PubMedGoogle Scholar
  39. 39.
    Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.CrossRefPubMedGoogle Scholar
  40. 40.
    Rashid-Kolvear F, Pintilie M, Done SJ. Telomere length on chromosome 17q shortens more than global telomere length in the development of breast cancer. Neoplasia. 2007;9:265–70.CrossRefPubMedGoogle Scholar
  41. 41.
    Hyun CL, Lee HE, Kim KS, et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol. 2008;61:317–21.CrossRefPubMedGoogle Scholar
  42. 42.
    Lal P, Salazar PA, Ladanyi M, et al. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn. 2003;5:155–9.PubMedGoogle Scholar
  43. 43.
    Kanekawa A, Tsuji T, Oga A, et al. Chromosome 17 abnormalities in squamous cell carcinoma of the oral cavity, and its relationship with p53 and Bcl-2 expression. Anticancer Res. 1999;19:81–6.PubMedGoogle Scholar
  44. 44.
    Voravud N, Shin DM, Ro JY, et al. Increased polysomies of chromosomes 7 and 17 during head and neck multistage tumorigenesis. Cancer Res. 1993;53:2874–83.PubMedGoogle Scholar
  45. 45.
    Field JK, Spandidos DA, Yiagnisis M, et al. C-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Res. 1992;12:613–9.PubMedGoogle Scholar
  46. 46.
    Kearsley JH, Leonard JH, Walsh MD, et al. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology. 1991;23:189–94.CrossRefPubMedGoogle Scholar
  47. 47.
    Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771–7.PubMedGoogle Scholar
  48. 48.
    Weinstein GS, Nuamah IF, Tucker J, et al. Evaluation of HER-2/neu (c-erbB-2) oncogene expression in whole organ sections of supraglottic squamous cell carcinoma. Ann Otol Rhinol Laryngol. 1996;105:275–9.PubMedGoogle Scholar
  49. 49.
    Saez A, Andreu FJ, Segui MA, et al. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases. Breast. 2006;15:519–27.CrossRefPubMedGoogle Scholar
  50. 50.
    Hanna WM, Kwok K. Chromogenic in situ hybridization: a viable alternative to fluorescence in situ hybridization in the HER2 testing algorithm. Mod Pathol. 2006;19:481–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Bilous M, Morey A, Armes J, et al. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry. Pathology. 2006;38:120–4.CrossRefPubMedGoogle Scholar
  52. 52.
    Sauer T, Wiedswang G, Boudjema G, et al. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice? APMIS. 2003;111:444–50.CrossRefPubMedGoogle Scholar
  53. 53.
    O-Charoenrat P, Rhys-Evans P, Eccles S. Characterization of ten newly-derived human head and neck squamous carcinoma cell lines with special reference to c-erbB proto-oncogene expression. Anticancer Res. 2001;21:1953–63.PubMedGoogle Scholar
  54. 54.
    Freier K, Joos S, Flechtenmacher C, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res. 2003;63:1179–82.PubMedGoogle Scholar
  55. 55.
    Bose S, Mohammed M, Shintaku P, et al. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J. 2001;7:337–44.CrossRefPubMedGoogle Scholar
  56. 56.
    Charuruks N, Shin DM, Voravud N, et al. Genetic instabilities of chromosome 9, 17 and accumulation of p53 overexpression during multistage tumorigesis in head and neck cancer. J Med Assoc Thai. 1996;79(Suppl 1):S104–12.PubMedGoogle Scholar
  57. 57.
    Shin DM, Charuruks N, Lippman SM, et al. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev. 2001;10:603–9.PubMedGoogle Scholar
  58. 58.
    Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18–43.PubMedGoogle Scholar

Copyright information

© Humana 2009

Authors and Affiliations

  • Dimitrios Papavasileiou
    • 1
  • Konstantinos Tosios
    • 1
  • Panos Christopoulos
    • 1
  • Nikolaos Goutas
    • 2
  • Dimitrios Vlachodimitropoulos
    • 2
  1. 1.Department of Oral Pathology and Surgery, Faculty of DentistryNational and Kapodestrian University of AthensAthensGreece
  2. 2.Department of Forensic Pathology and Toxicology, Medical SchoolNational and Kapodestrian University of AthensAthensGreece

Personalised recommendations